Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
News Medical on MSN7d
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular eventsResearchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.
GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback